Skip to main content
Erschienen in: Current Neurology and Neuroscience Reports 8/2014

01.08.2014 | Demyelinating Disorders (DN Bourdette and V Yadav, Section Editors)

Botulinum Toxin for Symptomatic Therapy in Multiple Sclerosis

verfasst von: Michelle H. Cameron, Francois Bethoux, Nina Davis, Meredith Frederick

Erschienen in: Current Neurology and Neuroscience Reports | Ausgabe 8/2014

Einloggen, um Zugang zu erhalten

Abstract

Botulinum toxin (BT) is a neurotoxin that paralyzes muscles by inhibiting release of acetylcholine from presynaptic vesicles at the neuromuscular junction. In people with multiple sclerosis (MS), clinical experience and research studies show that local injection of minute quantities of BT can temporarily control skeletal muscle spasticity, bladder detrusor hyperreflexia, and tremor. Specifically, BT injections have been shown to reduce muscle tone and improve passive function, and possibly improve active function, in patients with spasticity. Injection of BT into the bladder wall is a uniquely effective, safe, and durable treatment in patients with neurogenic detrusor hyperreflexia due to MS who have insufficient response or who do not tolerate oral antimuscarinic medications. This procedure has markedly reduced the need for indwelling catheters and bladder surgery. In addition, a recent study suggests BT may be effective for select patients with MS-associated upper extremity tremor. Appropriate use of BT can improve quality of life for many patients with MS.
Literatur
1.
Zurück zum Zitat Chen S. Clinical uses of botulinum neurotoxins: current indications, limitations and future developments. Toxins (Basel). 2012;4:913–39.CrossRef Chen S. Clinical uses of botulinum neurotoxins: current indications, limitations and future developments. Toxins (Basel). 2012;4:913–39.CrossRef
2.
Zurück zum Zitat Lance J. Symposium synopsis. In: Feldman RG, Young RR, Koella WP, editors. Spasticity: disordered motor control. Chicago: Year Book Medical Publishers; 1980. p. 485–94. Lance J. Symposium synopsis. In: Feldman RG, Young RR, Koella WP, editors. Spasticity: disordered motor control. Chicago: Year Book Medical Publishers; 1980. p. 485–94.
3.
Zurück zum Zitat Rizzo MA, Hadjimichael OC, Preiningerova J, Vollmer TL. Prevalence and treatment of spasticity reported by multiple sclerosis patients. Mult Scler. 2004;10:589–95.PubMedCrossRef Rizzo MA, Hadjimichael OC, Preiningerova J, Vollmer TL. Prevalence and treatment of spasticity reported by multiple sclerosis patients. Mult Scler. 2004;10:589–95.PubMedCrossRef
4.
Zurück zum Zitat Barnes MP, Kent RM, Semlyen JK, McMullen KM. Spasticity in multiple sclerosis. Neurorehabil Neural Repair. 2003;17:66–70.PubMedCrossRef Barnes MP, Kent RM, Semlyen JK, McMullen KM. Spasticity in multiple sclerosis. Neurorehabil Neural Repair. 2003;17:66–70.PubMedCrossRef
5.
Zurück zum Zitat Simpson DM, Gracies JM, Graham HK, Miyasaki JM, Naumann M, Russman B, et al. Assessment: botulinum neurotoxin for the treatment of spasticity (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2008;70:1691–8.PubMedCrossRef Simpson DM, Gracies JM, Graham HK, Miyasaki JM, Naumann M, Russman B, et al. Assessment: botulinum neurotoxin for the treatment of spasticity (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2008;70:1691–8.PubMedCrossRef
6.
Zurück zum Zitat Consortium of Multiple Sclerosis Centers. Spasticity management in multiple sclerosis. Hackensack, NJ; 2003. Consortium of Multiple Sclerosis Centers. Spasticity management in multiple sclerosis. Hackensack, NJ; 2003.
7.
Zurück zum Zitat Gold R, Oreja-Guevara C. Advances in the management of multiple sclerosis spasticity: multiple sclerosis spasticity guidelines. Expert Rev Neurother. 2013;13:55–9.PubMedCrossRef Gold R, Oreja-Guevara C. Advances in the management of multiple sclerosis spasticity: multiple sclerosis spasticity guidelines. Expert Rev Neurother. 2013;13:55–9.PubMedCrossRef
8.
Zurück zum Zitat Shakespeare DT, Boggild M, Young C. Anti-spasticity agents for multiple sclerosis. Cochrane Database Syst Rev. 2003;4, CD001332.PubMed Shakespeare DT, Boggild M, Young C. Anti-spasticity agents for multiple sclerosis. Cochrane Database Syst Rev. 2003;4, CD001332.PubMed
9.
Zurück zum Zitat Snow BJ, Tsui JK, Bhatt MH, Varelas M, Hashimoto SA, Calne DB. Treatment of spasticity with botulinum toxin: a double-blind study. Ann Neurol. 1990;28:512–5.PubMedCrossRef Snow BJ, Tsui JK, Bhatt MH, Varelas M, Hashimoto SA, Calne DB. Treatment of spasticity with botulinum toxin: a double-blind study. Ann Neurol. 1990;28:512–5.PubMedCrossRef
10.
Zurück zum Zitat Grazko MA, Polo KB, Jabbari B. Botulinum toxin A for spasticity, muscle spasms, and rigidity. Neurology. 1995;45:712–7.PubMedCrossRef Grazko MA, Polo KB, Jabbari B. Botulinum toxin A for spasticity, muscle spasms, and rigidity. Neurology. 1995;45:712–7.PubMedCrossRef
11.
Zurück zum Zitat Hyman N, Barnes M, Bhakta B, Cozens A, Bakheit M, Kreczy-Kleedorfer B, et al. Botulinum toxin (Dysport) treatment of hip adductor spasticity in multiple sclerosis: a prospective, randomised, double blind, placebo controlled, dose ranging study. J Neurol Neurosurg Psychiatry. 2000;68:707–12.PubMedCentralPubMedCrossRef Hyman N, Barnes M, Bhakta B, Cozens A, Bakheit M, Kreczy-Kleedorfer B, et al. Botulinum toxin (Dysport) treatment of hip adductor spasticity in multiple sclerosis: a prospective, randomised, double blind, placebo controlled, dose ranging study. J Neurol Neurosurg Psychiatry. 2000;68:707–12.PubMedCentralPubMedCrossRef
12.
Zurück zum Zitat Sheean G. Botulinum toxin treatment of adult spasticity: a benefit-risk assessment. Drug Saf. 2006;29:31–48.PubMedCrossRef Sheean G. Botulinum toxin treatment of adult spasticity: a benefit-risk assessment. Drug Saf. 2006;29:31–48.PubMedCrossRef
13.••
Zurück zum Zitat Picelli A, Lobba D, Midiri A, Prandi P, Melotti C, Baldessarelli S, et al. Botulinum toxin injection into the forearm muscles for wrist and fingers spastic overactivity in adults with chronic stroke: a randomized controlled trial comparing three injection techniques. Clin Rehabil. 2014;28:232–42. This study provides evidence regarding the impact of instrumented muscle localization on the efficacy of BT-A injections. Sixty patients with poststroke upper extremity spasticity were randomized into three groups (manual needle placement, electrical stimulation guidance, ultrasonography guidance). The injections were performed in the wrist and finger flexor muscles. At 4 weeks, there was a significantly larger improvement on all outcome measures in the electrical stimulation and ultrasonography placement groups compared with the manual needle placement group. No significant difference was observed between the two instrumented injection guidance techniques.PubMedCrossRef Picelli A, Lobba D, Midiri A, Prandi P, Melotti C, Baldessarelli S, et al. Botulinum toxin injection into the forearm muscles for wrist and fingers spastic overactivity in adults with chronic stroke: a randomized controlled trial comparing three injection techniques. Clin Rehabil. 2014;28:232–42. This study provides evidence regarding the impact of instrumented muscle localization on the efficacy of BT-A injections. Sixty patients with poststroke upper extremity spasticity were randomized into three groups (manual needle placement, electrical stimulation guidance, ultrasonography guidance). The injections were performed in the wrist and finger flexor muscles. At 4 weeks, there was a significantly larger improvement on all outcome measures in the electrical stimulation and ultrasonography placement groups compared with the manual needle placement group. No significant difference was observed between the two instrumented injection guidance techniques.PubMedCrossRef
14.
Zurück zum Zitat Giovannelli M, Borriello G, Castri P, Prosperini L, Pozzilli C. Early physiotherapy after injection of botulinum toxin increases the beneficial effects on spasticity in patients with multiple sclerosis. Clin Rehabil. 2007;21:331–7.PubMedCrossRef Giovannelli M, Borriello G, Castri P, Prosperini L, Pozzilli C. Early physiotherapy after injection of botulinum toxin increases the beneficial effects on spasticity in patients with multiple sclerosis. Clin Rehabil. 2007;21:331–7.PubMedCrossRef
15.
Zurück zum Zitat Litwiller SE, Frohman EM, Zimmern PE. Multiple sclerosis and the urologist. J Urol. 1999;161:743–57.PubMedCrossRef Litwiller SE, Frohman EM, Zimmern PE. Multiple sclerosis and the urologist. J Urol. 1999;161:743–57.PubMedCrossRef
16.
Zurück zum Zitat Kalsi V, Apostolidis A, Popat R, Gonzales G, Fowler CJ, Dasgupta P. Quality of life changes in patients with neurogenic versus idiopathic detrusor overactivity after intradetrusor injections of botulinum neurotoxin type A and correlations with lower urinary tract symptoms and urodynamic changes. Eur Urol. 2006;49:528–35.PubMedCrossRef Kalsi V, Apostolidis A, Popat R, Gonzales G, Fowler CJ, Dasgupta P. Quality of life changes in patients with neurogenic versus idiopathic detrusor overactivity after intradetrusor injections of botulinum neurotoxin type A and correlations with lower urinary tract symptoms and urodynamic changes. Eur Urol. 2006;49:528–35.PubMedCrossRef
17.
Zurück zum Zitat Schurch B, de Seze M, Denys P, Chartier-Kastler E, Haab F, Everaert K, et al. Botulinum toxin type A is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study. J Urol. 2005;174:196–200.PubMedCrossRef Schurch B, de Seze M, Denys P, Chartier-Kastler E, Haab F, Everaert K, et al. Botulinum toxin type A is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study. J Urol. 2005;174:196–200.PubMedCrossRef
18.
Zurück zum Zitat Sussman D, Patel V, Del Popolo G, Lam W, Globe D, Pommerville P. Treatment satisfaction and improvement in health-related quality of life with onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity. Neurourol Urodyn. 2013;32:242–9.PubMedCrossRef Sussman D, Patel V, Del Popolo G, Lam W, Globe D, Pommerville P. Treatment satisfaction and improvement in health-related quality of life with onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity. Neurourol Urodyn. 2013;32:242–9.PubMedCrossRef
19.
Zurück zum Zitat Schurch B, Stohrer M, Kramer G, Schmid DM, Gaul G, Hauri D. Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results. J Urol. 2000;164:692–7.PubMedCrossRef Schurch B, Stohrer M, Kramer G, Schmid DM, Gaul G, Hauri D. Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results. J Urol. 2000;164:692–7.PubMedCrossRef
20.
Zurück zum Zitat Herschorn S, Gajewski J, Ethans K, Corcos J, Carlson K, Bailly G, et al. Efficacy of botulinum toxin A injection for neurogenic detrusor overactivity and urinary incontinence: a randomized, double-blind trial. J Urol. 2011;185:2229–35.PubMedCrossRef Herschorn S, Gajewski J, Ethans K, Corcos J, Carlson K, Bailly G, et al. Efficacy of botulinum toxin A injection for neurogenic detrusor overactivity and urinary incontinence: a randomized, double-blind trial. J Urol. 2011;185:2229–35.PubMedCrossRef
21.••
Zurück zum Zitat Ginsberg D, Gousse A, Keppenne V, Sievert KD, Thompson C, Lam W, et al. Phase 3 efficacy and tolerability study of onabotulinumtoxinA for urinary incontinence from neurogenic detrusor overactivity. J Urol. 2012;187:2131–9. This international, multicenter, double-blind, randomized, placebo-controlled study included the largest number of MS subjects, 227, more than all prior efficacy trials combined. The primary outcome was the change from the baseline in number of weekly incontinence episodes. Secondary outcomes included bladder capacity, maximum detrusor pressure at initial involuntary contraction, and quality-of-life summary score on a validated questionnaire. At 2, 6, and 12 weeks of treatment, all subjects receiving BT-A demonstrated a statistically significant decrease in the number of incontinence episodes compared with those receiving placebo. No differences were noted between responses in patients treated with 200 units versus 300 units. Additionally, the dry rates for those treated with 200 units and 300 units were 36% and 42%, respectively. Similar statistically significant decreases in detrusor pressure and bladder capacity in the two treatment arms (200 units and 300 units compared with placebo) were observed as well. Quality of life was significantly improved in all of those receiving BT-A. This is the most comprehensive and rigorous study of the use of BT-A in NDO due to MS, and its findings validate the efficacy, safety, and improvement in well-being that derive from detrusor injection of BT-A.PubMedCrossRef Ginsberg D, Gousse A, Keppenne V, Sievert KD, Thompson C, Lam W, et al. Phase 3 efficacy and tolerability study of onabotulinumtoxinA for urinary incontinence from neurogenic detrusor overactivity. J Urol. 2012;187:2131–9. This international, multicenter, double-blind, randomized, placebo-controlled study included the largest number of MS subjects, 227, more than all prior efficacy trials combined. The primary outcome was the change from the baseline in number of weekly incontinence episodes. Secondary outcomes included bladder capacity, maximum detrusor pressure at initial involuntary contraction, and quality-of-life summary score on a validated questionnaire. At 2, 6, and 12 weeks of treatment, all subjects receiving BT-A demonstrated a statistically significant decrease in the number of incontinence episodes compared with those receiving placebo. No differences were noted between responses in patients treated with 200 units versus 300 units. Additionally, the dry rates for those treated with 200 units and 300 units were 36% and 42%, respectively. Similar statistically significant decreases in detrusor pressure and bladder capacity in the two treatment arms (200 units and 300 units compared with placebo) were observed as well. Quality of life was significantly improved in all of those receiving BT-A. This is the most comprehensive and rigorous study of the use of BT-A in NDO due to MS, and its findings validate the efficacy, safety, and improvement in well-being that derive from detrusor injection of BT-A.PubMedCrossRef
22.
Zurück zum Zitat Mehnert U, Birzele J, Reuter K, Schurch B. The effect of botulinum toxin type A on overactive bladder symptoms in patients with multiple sclerosis: a pilot study. J Urol. 2010;184:1011–6.PubMedCrossRef Mehnert U, Birzele J, Reuter K, Schurch B. The effect of botulinum toxin type A on overactive bladder symptoms in patients with multiple sclerosis: a pilot study. J Urol. 2010;184:1011–6.PubMedCrossRef
23.
Zurück zum Zitat Kuo HC. Bladder base/trigone injection is safe and as effective as bladder body injection of onabotulinumtoxinA for idiopathic detrusor overactivity refractory to antimuscarinics. Neurourol Urodyn. 2011;30:1242–8.PubMed Kuo HC. Bladder base/trigone injection is safe and as effective as bladder body injection of onabotulinumtoxinA for idiopathic detrusor overactivity refractory to antimuscarinics. Neurourol Urodyn. 2011;30:1242–8.PubMed
24.
Zurück zum Zitat Grosse J, Kramer G, Stohrer M. Success of repeat detrusor injections of botulinum a toxin in patients with severe neurogenic detrusor overactivity and incontinence. Eur Urol. 2005;47:653–9.PubMedCrossRef Grosse J, Kramer G, Stohrer M. Success of repeat detrusor injections of botulinum a toxin in patients with severe neurogenic detrusor overactivity and incontinence. Eur Urol. 2005;47:653–9.PubMedCrossRef
25.
Zurück zum Zitat Gaillet S, Bardot P, Bernuz B, Boissier R, Lenne-Aurier K, Thiry-Escudier I, et al. Five years follow-up study and failures analysis of botulinum toxin repeated injections to treat neurogenic detrusor overactivity. Prog Urol. 2012;22:1064–70.PubMedCrossRef Gaillet S, Bardot P, Bernuz B, Boissier R, Lenne-Aurier K, Thiry-Escudier I, et al. Five years follow-up study and failures analysis of botulinum toxin repeated injections to treat neurogenic detrusor overactivity. Prog Urol. 2012;22:1064–70.PubMedCrossRef
26.
Zurück zum Zitat Veeratterapillay R, Harding C, Teo L, Vasdev N, Abroaf A, Dorkin T, et al. Discontinuation rates and inter-injection interval for repeated intravesical botulinum toxin type A injections for detrusor overactivity. Int J Urol. 2014;21:175–8.PubMedCrossRef Veeratterapillay R, Harding C, Teo L, Vasdev N, Abroaf A, Dorkin T, et al. Discontinuation rates and inter-injection interval for repeated intravesical botulinum toxin type A injections for detrusor overactivity. Int J Urol. 2014;21:175–8.PubMedCrossRef
27.
Zurück zum Zitat Apostodolis A, Haferkamp A, Aoki KR. Understanding the role of botulinum toxin A in the treatment of the overactive bladder—more than just muscle relaxation. Eur Urol Suppl. 2006;5:670–8.CrossRef Apostodolis A, Haferkamp A, Aoki KR. Understanding the role of botulinum toxin A in the treatment of the overactive bladder—more than just muscle relaxation. Eur Urol Suppl. 2006;5:670–8.CrossRef
28.
Zurück zum Zitat Game X, Castel-Lacanal E, Bentaleb Y, Thiry-Escudie I, De Boissezon X, Malavaud B, et al. Botulinum toxin A detrusor injections in patients with neurogenic detrusor overactivity significantly decrease the incidence of symptomatic urinary tract infections. Eur Urol. 2008;53:613–8.PubMedCrossRef Game X, Castel-Lacanal E, Bentaleb Y, Thiry-Escudie I, De Boissezon X, Malavaud B, et al. Botulinum toxin A detrusor injections in patients with neurogenic detrusor overactivity significantly decrease the incidence of symptomatic urinary tract infections. Eur Urol. 2008;53:613–8.PubMedCrossRef
29.
Zurück zum Zitat Alusi SH, Worthington J, Glickman S, Bain PG. A study of tremor in multiple sclerosis. Brain. 2001;124:720–30.PubMedCrossRef Alusi SH, Worthington J, Glickman S, Bain PG. A study of tremor in multiple sclerosis. Brain. 2001;124:720–30.PubMedCrossRef
30.
Zurück zum Zitat Labiano-Fontcuberta A, Benito-Leon J. Understanding tremor in multiple sclerosis: prevalence, pathological anatomy, and pharmacological and surgical approaches to treatment. Tremor Other Hyperkinet Mov. 2012;2:1–10. Labiano-Fontcuberta A, Benito-Leon J. Understanding tremor in multiple sclerosis: prevalence, pathological anatomy, and pharmacological and surgical approaches to treatment. Tremor Other Hyperkinet Mov. 2012;2:1–10.
31.
Zurück zum Zitat Clarke CE. Botulinum toxin type A in cerebellar tremor caused by multiple sclerosis. Eur J Neurol. 1997;4:68–71.PubMedCrossRef Clarke CE. Botulinum toxin type A in cerebellar tremor caused by multiple sclerosis. Eur J Neurol. 1997;4:68–71.PubMedCrossRef
32.
Zurück zum Zitat Alusi SH, Worthington J, Glickman S, Findley LJ, Bain PG. Evaluation of three different ways of assessing tremor in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2000;68:756–60.PubMedCentralPubMedCrossRef Alusi SH, Worthington J, Glickman S, Findley LJ, Bain PG. Evaluation of three different ways of assessing tremor in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2000;68:756–60.PubMedCentralPubMedCrossRef
33.
Zurück zum Zitat Brin MF, Lyons KE, Doucette J, Adler CH, Caviness JN, Comella CL, et al. A randomized, double masked, controlled trial of botulinum toxin type A in essential hand tremor. Neurology. 2001;56:1523–8.PubMedCrossRef Brin MF, Lyons KE, Doucette J, Adler CH, Caviness JN, Comella CL, et al. A randomized, double masked, controlled trial of botulinum toxin type A in essential hand tremor. Neurology. 2001;56:1523–8.PubMedCrossRef
Metadaten
Titel
Botulinum Toxin for Symptomatic Therapy in Multiple Sclerosis
verfasst von
Michelle H. Cameron
Francois Bethoux
Nina Davis
Meredith Frederick
Publikationsdatum
01.08.2014
Verlag
Springer US
Erschienen in
Current Neurology and Neuroscience Reports / Ausgabe 8/2014
Print ISSN: 1528-4042
Elektronische ISSN: 1534-6293
DOI
https://doi.org/10.1007/s11910-014-0463-7

Weitere Artikel der Ausgabe 8/2014

Current Neurology and Neuroscience Reports 8/2014 Zur Ausgabe

Neuro-Ophthalmology (A Kawasaki, Section Editor)

Obstructive Sleep Apnea and Optic Neuropathy: Is There a Link?

Behavior (H Kirshner, Section Editor)

Creativity and Neurological Disease

Behavior (H Kirshner, Section Editor)

Pathology in Primary Progressive Aphasia Syndromes

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Sozialer Aufstieg verringert Demenzgefahr

24.05.2024 Demenz Nachrichten

Ein hohes soziales Niveau ist mit die beste Versicherung gegen eine Demenz. Noch geringer ist das Demenzrisiko für Menschen, die sozial aufsteigen: Sie gewinnen fast zwei demenzfreie Lebensjahre. Umgekehrt steigt die Demenzgefahr beim sozialen Abstieg.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Was nützt die Kraniektomie bei schwerer tiefer Hirnblutung?

17.05.2024 Hirnblutung Nachrichten

Eine Studie zum Nutzen der druckentlastenden Kraniektomie nach schwerer tiefer supratentorieller Hirnblutung deutet einen Nutzen der Operation an. Für überlebende Patienten ist das dennoch nur eine bedingt gute Nachricht.

Thrombektomie auch bei großen Infarkten von Vorteil

16.05.2024 Ischämischer Schlaganfall Nachrichten

Auch ein sehr ausgedehnter ischämischer Schlaganfall scheint an sich kein Grund zu sein, von einer mechanischen Thrombektomie abzusehen. Dafür spricht die LASTE-Studie, an der Patienten und Patientinnen mit einem ASPECTS von maximal 5 beteiligt waren.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.